Trial Profile

ABT 072 vs ABT 333 in patients with hepatitis C also receiving peginterferon alfa-2a + ribavirin: a dose-ranging study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABT 072 (Primary) ; Dasabuvir; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Abbott Laboratories

Most Recent Events

10 May 2012 New trial record
22 Apr 2012 Interim results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com